本文系基于公开资料撰写,仅作为信息交流之用,不构成任何投资建议。司美格鲁肽与替尔泊肽均成为“药王级”产品,似乎GLP-1已然兑现了市场对它的期待。然而,随着研究的深入与市场竞争的加剧,现有GLP-1的痛点逐渐显现,围绕GLP-1的探索远未停歇,而是迈向了更为多元且深入的新征程。两大行业巨头礼来与诺和诺德,看似稳坐云端宝座,实则危机四伏,各路豪强对GLP-1下半场虎视眈眈。GLP-1争夺战并未结束,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.